Evidence map›Paper›PMID 42051354›Full record

ArticleClinical Medicine Insights. Oncology2026

Transarterial Chemoembolization Combined With Lenvatinib in the Treatment of Intermediate-Stage Hepatocellular Carcinoma With Hypovascular Nodules: A Retrospective Cohort Study.

Jun Yang, Fei Shi, Nan Jiang, Shen Zhang, Yu Yin, Bin Yu, Wencong Feng, Hongao Chu, Caifang Ni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jun YangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0001-5483-5511
Fei ShiDepartment of Ultrasound Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Nan JiangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Shen ZhangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yu YinDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Bin YuDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Wencong FengDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hongao ChuDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Caifang NiDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To compare the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib vs TACE alone in intermediate-stage hepatocellular carcinoma (HCC) patients with hypovascular nodules. Methods: This retrospective study analyzed the clinical data of intermediate-stage HCC patients with hypovascular nodules who underwent TACE. Patients were categorized into the TACE-Lenv combination group and the TACE monotherapy group according to their receipt of lenvatinib therapy. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), progression of hypovascular nodules, and treatment-related adverse events were recorded and analyzed. Results: The study enrolled 75 patients, with 40 allocated to the TACE-Lenv group and 35 to the TACE group. The combination therapy group demonstrated significantly higher ORR and DCR (92.5% vs 74.3%, Conclusions: The combination therapy of TACE and lenvatinib demonstrated excellent clinical efficacy in intermediate-stage HCC with hypovascular nodules and may therefore emerge as a preferred treatment option for this specific patient population.

Indexed as

Hepatocellular carcinomahypovascular nodulelenvatiniboverall survivaltransarterial chemoembolization

Identifiers

PMID42051354
PMCPMC13111896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.